title: Studies on the mechanism of interactions between anesthetic steroids and gamma-aminobutyric acidA receptors.
abstract: Functional interactions between steroidal anesthetics and gamma-aminobutyric acidA (GABAA) receptors have been examined with 36Cl- uptake measurements in rat cerebrocortical synaptoneurosomes. The primary effect of the steroids was to enhance the affinity of GABA for its receptors without much effect on the maximal uptake rate; the ED50 for GABA decreased from 66.4 +/- 5.7 to 8.9 +/- 1.2 microM in the presence of 20 microM 3 alpha,21-dihydroxy-5 alpha-pregnan-20-one. Stimulation of 36Cl- uptake by high concentrations of the anesthetic steroid in the absence of exogenous GABA was not due to direct stimulation of GABAA receptors, as currently proposed, but is due to enhanced action of endogenous GABA, inasmuch as the steroid markedly increases GABA affinity for the receptors. Typically, endogenous GABA was maintained at near 1 microM by a Na(+)-dependent GABA transport system in the synaptoneurosomes. Elevation of its level with nipecotic acid, a specific inhibitor of the GABA transport system, or reduction with GABase, a GABA-scavenging system, increased or decreased, respectively, the steroid-induced bicuculline-sensitive 36Cl- uptake. At low concentrations of GABA (less than 2 microM), the stimulatory effect of 3 alpha,21-dihydroxy-5 alpha-pregnan-20-one was markedly potentiated by pentobarbital but antagonized by 3 alpha,21-dihydroxy-5 alpha-pregnan-20-one, a partial agonist of higher affinity. These observations, along with the structure-activity relationships of steroid analogs, strongly suggest the existence of a specific binding site for the steroids in GABAA receptors and led us to propose a minimal model in which two key common functional groups of anesthetic steroids, 3 alpha-OH- and 17 beta-polar substituents, interact with GABAA receptors (probably through hydrogen bondings) while their hydrophobic backbone remains in contact with the fatty acyl chains of membrane phospholipids.
authors.affiliation: CNS Diseases Research, Upjohn Company, Kalamazoo, Michigan 49001.
authors.forename: W B
authors.initials: WB
authors.lastname: Im
authors.forename: D P
authors.initials: DP
authors.lastname: Blakeman
authors.forename: J P
authors.initials: JP
authors.lastname: Davis
authors.forename: D E
authors.initials: DE
authors.lastname: Ayer
mesh_terms: D000777:Anesthetics / Q000494:pharmacology*; D000818:Animals; D002712:Chlorides / Q000378:metabolism; D003900:Desoxycorticosterone / Q000031:analogs & derivatives* / Q000494:pharmacology; D066298:In Vitro Techniques; D007700:Kinetics; D009557:Nipecotic Acids / Q000494:pharmacology; D010424:Pentobarbital / Q000494:pharmacology; D011280:Pregnanolone; D011374:Progesterone / Q000031:analogs & derivatives* / Q000494:pharmacology; D011392:Proline / Q000031:analogs & derivatives*; D051381:Rats; D011963:Receptors, GABA-A / Q000187:drug effects* / Q000378:metabolism; D013570:Synaptic Membranes; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
chemical_list: D000777:Anesthetics; D002712:Chlorides; D009557:Nipecotic Acids; D011963:Receptors, GABA-A; C030278:nipecotic acid; D003900:Desoxycorticosterone; C009413:tetrahydrodeoxycorticosterone; D011374:Progesterone; D005680:gamma-Aminobutyric Acid; D011392:Proline; D011280:Pregnanolone; C010983:homoproline; D010424:Pentobarbital